Targeting JAK2 V617F in MPNs with interferon alpha and arsenic trioxide
From the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the combination of interferon and arsenic trioxide to target JAK2 V617F in myeloproliferative neoplasms (MPNs). Promising preclinical results have been seen, showing specific and synergistric targeting of the mutation.
Видео Targeting JAK2 V617F in MPNs with interferon alpha and arsenic trioxide канала VJHemOnc – Video Journal of Hematology & HemOnc
Видео Targeting JAK2 V617F in MPNs with interferon alpha and arsenic trioxide канала VJHemOnc – Video Journal of Hematology & HemOnc
Показать
Комментарии отсутствуют
Информация о видео
6 декабря 2018 г. 17:56:28
00:02:39
Другие видео канала
POLARIX: Polatuzumab vedotin and R-CHP superior to R-CHOP in DLBCLChoosing between isatuximab & daratumumab in multiple myelomaDefining precursor states in multiple myelomaMomelotinib: a promising drug for patients with myelofibrosisThe promise of mutant CALR antibodies for the treatment of MPNsIPSS-R vs IPSS-M for MDSMRD Focus: why measurable residual disease testing is the futureUpdates from a Phase I study evaluating dendritic cell therapy, cryosurgery & pembrolizumab in NHLSURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemiaInvestigating melflufen: a peptidase enhanced cytotoxic for myelomaInsights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLLGENESIS: Motixafortide prior to HCT in patients with MMPV-PINPOINT: a study investigating the diagnosis and management of polycythemia vera in the UKSubcutaneous ravulizumab trial for paroxysmal nocturnal hemoglobinuria treatmentApproval of teclistamab in triple-class refractory multiple myelomaLow-dose gemcitabine for advanced CTCLEvolving CLL treatments: creating choices and igniting discussionsAn insight into Langerhans cell histiocytosis and advances in treatment approachesThe importance of improving immune function in CLLChallenges and future perspectives for minimal residual disease (MRD) in multiple myelomaDiscussing FLT3-mutated AML: top ASH data, triplets, and exciting future strategies